Okabe-Kado Junko, Kasukabe Takashi, Honma Yoshio, Hanada Ryoji, Nakagawara Akira, Kaneko Yasuhiko
Research Institute for Clinical Oncology, Saitama Cancer Center, 818 Komuro, Ina-machi, Kitaadachi-gun, Saitama 362-0806, Japan.
Cancer Sci. 2005 Oct;96(10):653-60. doi: 10.1111/j.1349-7006.2005.00091.x.
We have previously reported that NM23 genes are overexpressed in various hematological malignancies and that serum NM23-H1 protein levels are useful for predicting patient outcomes. In this study we assessed the clinical implications of serum NM23-H1 protein on neuroblastoma. We examined serum NM23-H1 protein levels in 217 patients with neuroblastoma, including 131 found by mass-screening and 86 found clinically by an enzyme-linked immunosorbent assay, and determined the association between levels of this protein, and known prognostic factors or the clinical outcome. The serum NM23-H1 protein level was higher in neuroblastoma patients than in control children (P < 0.0001). Patients with MYCN amplification had higher serum NM23-H1 levels than those with a single copy of MYCN. Overall survival was assessed in the 86 patients found clinically, and was found to be worse in patients with higher serum MN23-H1 levels (> or = 250 ng/mL) than in those with lower levels (< 250 ng/mL; P = 0.034). The higher level of NM23-H1 was correlated with a worse outcome in patients with a single MYCN copy, or in those younger than 12 months of age. Serum NM23-H1 protein levels may contribute to predictions of clinical outcome in patients with neuroblastoma.
我们之前曾报道，NM23基因在多种血液系统恶性肿瘤中过表达，且血清NM23-H1蛋白水平有助于预测患者预后。在本研究中，我们评估了血清NM23-H1蛋白对神经母细胞瘤的临床意义。我们检测了217例神经母细胞瘤患者的血清NM23-H1蛋白水平，其中131例通过大规模筛查发现，86例通过酶联免疫吸附测定临床发现，并确定了该蛋白水平与已知预后因素或临床结局之间的关联。神经母细胞瘤患者的血清NM23-H1蛋白水平高于对照儿童（P < 0.0001）。MYCN扩增的患者血清NM23-H1水平高于MYCN单拷贝的患者。对临床发现的86例患者评估了总生存期，发现血清MN23-H1水平较高（≥250 ng/mL）的患者总生存期比水平较低（< 250 ng/mL；P = 0.034）的患者更差。NM23-H1水平较高与MYCN单拷贝患者或12个月以下患者的预后较差相关。血清NM23-H1蛋白水平可能有助于预测神经母细胞瘤患者的临床结局。
